A Phase 1, Single Center, Randomized, 4-way Crossover, Double Blinded, Placebo And Moxifloxacin Controlled Study To Evaluate The Effect Of Glasdegib On The Cardiac Repolarization In Healthy Subjects

Trial Profile

A Phase 1, Single Center, Randomized, 4-way Crossover, Double Blinded, Placebo And Moxifloxacin Controlled Study To Evaluate The Effect Of Glasdegib On The Cardiac Repolarization In Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Glasdegib (Primary) ; Moxifloxacin
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Colorectal cancer; Haematological malignancies; Myelodysplastic syndromes; Myelofibrosis; Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 05 Jul 2017 Planned End Date changed from 23 Oct 2017 to 16 Oct 2017.
    • 05 Jul 2017 Planned primary completion date changed from 25 Sep 2017 to 23 Sep 2017.
    • 05 Jul 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top